Clinical Trials
74
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (64 trials with phase data)• Click on a phase to view related trials
Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression
- Conditions
- Venous Vascular Closure
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 352
- Registration Number
- NCT05554471
- Locations
- 🇺🇸
Arizona Cardiovascular Research Center, Phoenix, Arizona, United States
🇺🇸Colorado Heart and Vascular PC, Lakewood, Colorado, United States
🇺🇸Palm Vascular Centers, Miami Beach, Florida, United States
PMCF Study for Cardiology Access Procedures
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05543096
- Locations
- 🇦🇹
Kepler Universitätsklinikum GmbH, Linz, Austria
🇦🇹Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹ST. Poelten, St. Poelten, Austria
PMCF Study for Peripheral Arteries Below the Knee (BTK)
- Conditions
- Peripheral Artery Disease
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 102
- Registration Number
- NCT05444660
- Locations
- 🇦🇹
Tirol Kliniken GmbH, Innsbruck, Austria
🇦🇹Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria
🇦🇹Medizinische Universität, Wien, Austria
Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access
- Conditions
- Peripheral Arterial Disease
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 151
- Registration Number
- NCT05399680
- Locations
- 🇦🇹
Univ Klinikum LKG Graz, Graz, Austria
🇦🇹Klinikum Klagenfurt am Wörtherse, Klagenfurt, Austria
🇦🇹Hanusch Krankenhaus, Vienna, Austria
PMCF Study for Peripheral Arteries Above the Knee (ATK)
- Conditions
- Femoropopliteal StenosisAngiopathy, PeripheralPeripheral Arterial Disease
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Cordis Corporation
- Target Recruit Count
- 387
- Registration Number
- NCT05312580
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹KABEG-Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria
🇦🇹Universitätsklinikum St. Pölten - Lilienfeld, St.Pölten, Austria
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
Cordis Launches 10,000-Patient Global Registry for SELUTION SLR Drug-Eluting Balloon
Cordis has initiated the SELUTION Global Coronary Registry, which will track real-world outcomes of their sirolimus-eluting balloon in up to 10,000 patients worldwide for five years.
SELUTION SLR Drug-Eluting Balloon Shows Exceptional 3-Year Patency Rates in Peripheral Artery Disease Trials
Cordis's SELUTION SLR Drug-Eluting Balloon demonstrated remarkable 81.5% primary patency at 3 years in the Japan Trial, establishing it as the only sirolimus-eluting technology with core-lab adjudicated 3-year patency exceeding 80%.
Endovascular Engineering Secures $42M Series B to Advance Novel Pulmonary Embolism Treatment
Endovascular Engineering has raised $42 million in Series B funding, co-led by 415 Capital and S3 Ventures, to advance their Hēlo PE Thrombectomy System for treating pulmonary embolism.